On May 4, 2020 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it will be presenting two abstracts at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Virtual Scientific Program to be held from May 29 to May 31, 2020 (Press release, Medicenna Therapeutics, MAY 4, 2020, View Source [SID1234556981]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first abstract has been selected for a poster discussion and will provide new data on tumor response as well as survival outcomes compared to a matched Synthetic Control Arm ("SCA"). Details of the poster discussion presentation are below:
Presenter:
Dr. John Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins
Distinguished Professor and Chair of Neurosurgery, Duke University School of
Medicine
Title:
"MDNA55 survival in recurrent glioblastoma ("rGBM") patients expressing the
interleukin-4 receptor ("IL4R") as compared to a matched synthetic control"
Abstract #:
2513
Session Title:
CNS Tumors
Discussant:
Dr. Ian Parney, MD, PhD
The second abstract will present pre-clinical data including non-human primate data for MDNA11, one of Medicenna’s IL2 Superkine candidates. Details of the poster presentation are below:
Presenter:
Dr. Moutih Rafei, PhD, Associate Professor, Department of Pharmacology and
Physiology, Université de Montreal
Title:
"In vitro and in vivo characteristics of MDNA11: A long-acting ‘Beta-only’
IL-2 Superkine in syngeneic mice tumor models and non-human primates"
Abstract #:
3036
Session Title:
Developmental Therapeutics Immunotherapy
Presentations and posters will be available for on-demand viewing online at View Source beginning on May 29, 2020 at 8:00 a.m. ET.